This is a working overview of nicotinamide mononucleotide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-21 and is reviewed periodically as new material appears.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring with a ribose sugar and a phosphate group. The compound appears in cells across many organisms as an intermediate in the production of nicotinamide adenine dinucleotide, or NAD+. Because NMN sits close to NAD+ in metabolism, it has drawn interest in biochemistry and aging research. The molecule is not a dietary essential nutrient in the classical sense, and its presence in food is generally low and variable.
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
Research on NMN includes cell studies, animal experiments, and a growing number of human trials. Many early findings come from mice, where changes in NAD+ levels and metabolic markers have been reported. Human data are more limited, and questions remain about effective routes of administration, tissue distribution, and long-term effects. Some trials measure NAD+ in blood or tissue, while others assess physical function or metabolic outcomes. Regulatory status differs between countries, and NMN is not universally approved as a dietary supplement or therapeutic agent.
Nicotinamide mononucleotide, abbreviated NMN, is a nucleotide composed of nicotinamide, ribose, and phosphate. Its structure links nicotinamide to D-ribose 5-phosphate through a glycosidic bond, placing it in the pyridine nucleotide family. The compound exists in alpha and beta anomeric forms, and the beta form is the one used in NAD+ biosynthesis. NMN is not a protein or a hormone; it is a small water-soluble molecule that occurs in living cells as a metabolic intermediate.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
Chemically, NMN is described by the molecular formula C11H15N2O8P and a molecular mass near 334.22 g/mol. The beta anomer has a CAS Registry Number of 1094-61-7. It is typically supplied as a white to off-white powder for laboratory use. The molecule carries a phosphate group and a positively charged nicotinamide ring, giving it polar and water-soluble character. These properties influence how it is detected, purified, and stored in research and analytical laboratories.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Nucleotide derivative of nicotinamide |
| Molecular formula | C11H15N2O8P | Free acid form; salts may differ |
| Molar mass | 334.22 g/mol | Approximate value for free acid |
| CAS Registry Number | 1094-61-7 | Common beta isomer |
| Solubility | Water-soluble | Polar molecule; solubility varies with pH and form |
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
Beyond its intracellular synthesis, NMN can be taken up from the extracellular environment, although the routes are still debated. Some evidence points to direct transport into cells through specific transporters, while other work suggests dephosphorylation to nicotinamide riboside followed by cellular uptake. Once inside, NMN can be converted to NAD+ by NMN adenylyltransferases; the relative contribution of these routes may differ by tissue, species, and experimental conditions. Researchers continue to investigate which mechanisms dominate in intact organisms and how they affect measured NAD+ levels. Direct measurement in tissues remains technically challenging because NMN can be rapidly metabolized during sample collection.
NMN occurs in many living systems, including bacteria, yeast, plants, and mammals. Dietary sources are present in foods such as edamame, avocado, broccoli, and various meats, but amounts vary widely and are generally lower than those used in research settings. Laboratory production often relies on enzymatic synthesis or chemical phosphorylation of nicotinamide riboside, and commercial material is typically supplied as a white to off-white powder. Because NMN is hygroscopic and sensitive to heat, moisture, and pH extremes, its handling requires care to preserve identity and purity. Aqueous preparation should be done with attention to pH and temperature to limit hydrolysis.
=== Primary prevention === Primary prevention aims to reduce the risk factors before a disease or condition occurs. Sun protection is the most effective form of primary prevention of photoaging. The major methods of sun protection are sunscreen products, sun protective clothing, and reducing exposure to the sun, especially during peak sun hours (10 AM-4 PM in the spring and summer seasons). Broad-spectrum sunscreen products provide optimal coverage for protection against UV damage because they protect against both types of UVA rays (UVA1 and UVA2) along with UVB rays. Proper application methods and timing are important factors in proper sunscreen use. This includes using a proper quantity of sunscreen, applying sunscreen prior to sun exposure, and consistent reapplication (especially after exposure to water or sweat).
Thorium is much more similar to the transition metals zirconium and hafnium than to cerium in its ionization energies and redox potentials, and hence also in its chemistry: this transition-metal-like behaviour is the norm in the first half of the actinide series, from actinium to americium.
== Pharmacology == Pramlintide is an analogue of amylin, a small peptide hormone that is released into the bloodstream by the β cells of the pancreas along with insulin after a meal. Like insulin, amylin is completely absent in individuals with Type I diabetes. In synergy with endogenous amylin, pramlintide aids in the regulation of blood glucose by slowing gastric emptying, promoting satiety via hypothalamic receptors (different receptors than for GLP-1), and inhibiting inappropriate secretion of glucagon, a catabolic hormone that opposes the effects of insulin and amylin. Pramlintide also has effects in raising the acute first-phase insulin response threshold following a meal. Both a reduction in glycated hemoglobin and weight loss have been shown in insulin-treated patients with type 2 diabetes taking pramlintide as an adjunctive therapy.
Sources: en.wikipedia.org
The first reported protein synthesized by KAHA ligation was human GLP-1 (7-36). Since then, a variety of small proteins (up to 200 residues) have been synthesized, including ubiquitin and other similar modifier proteins, hormone proteins, nitrophorin 4, S100A4 and cyclic proteins. C-terminal ketoacid monomers are pre-loaded on resin via a linker for Fmoc-SPPS (Fmoc-based solid phase peptide synthesis). Initial research utilised sulfur ylide linkers, but more recently the group developed acid- and photo-labile ketoacid monomers that can be loaded directly on Rink Amide resin. The most commonly used N-terminal hydroxylamine is the 5-oxaproline, which results in a homoserine residue after ligation and O-N rearrangement.
However, a 2015 Cochrane review concluded: "low-quality evidence suggests that postoperative splinting may not improve outcomes and may impair outcomes by reducing active flexion. Further trials on this topic are urgently required".
Kirk Sorensen, former NASA scientist and chief nuclear technologist at Teledyne Brown Engineering, has long been a promoter of thorium fuel cycle and particularly liquid fluoride thorium reactors. In 2011, Sorensen founded Flibe Energy, a company aimed to develop 20–50 MW LFTR reactor designs to power military bases. In October 2010 GE Hitachi Nuclear Energy signed a memorandum of understanding with the operators of the US Department of Energy's Savannah River Site, which should allow the construction of a demonstration plant based on the company's S-PRISM fast breeder reactor prior to the design receiving full Nuclear Regulatory Commission licensing approval. In October 2011 The Independent reported that the UK Nuclear Decommissioning Authority (NDA) and senior advisers within the Department for Energy and Climate Change (DECC) had asked for technical and financial details of PRISM, partly as a means of reducing the country's plutonium stockpile. The traveling wave reactor proposed in a patent by Intellectual Ventures is a fast breeder reactor designed to not need fuel reprocessing during the decades-long lifetime of the reactor. The breed-burn wave in the TWR design does not move from one end of the reactor to the other but gradually from the inside out. Moreover, as the fuel's composition changes through nuclear transmutation, fuel rods are continually reshuffled within the core to optimize the neutron flux and fuel usage at any given point in time.
Sources: en.wikipedia.org
NMN is a naturally occurring nucleotide and an intermediate in NAD+ biosynthesis. It consists of nicotinamide attached to a ribose phosphate unit. Cells produce it through the salvage pathway.
NMN is converted to NAD+ by NMNAT enzymes. NAD+ is a coenzyme in redox reactions and a substrate for signaling enzymes. This relationship makes NMN a focus of NAD+ research.
No, NMN and nicotinamide riboside are distinct compounds. Nicotinamide riboside can be phosphorylated to form NMN inside cells. Both are studied as NAD+ precursors.
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide and an intermediate in NAD+ biosynthesis.